Hepatosplenic T-Cell Lymphoma: Causes, Symptoms & Prognosis

Hepatosplenic T-cell lymphoma (HSTCL) is a rare, aggressive blood cancer that accounts for roughly 1 to 2 percent of all peripheral T-cell lymphomas, primarily striking young adults with a median age around 35.¹ Unlike most lymphomas, it does not form the swollen lymph nodes people typically associate with the disease. Instead, malignant T cells infiltrate the liver, spleen, and bone marrow, making it notoriously difficult to diagnose and treat. The picture is not entirely hopeless, but understanding what drives this lymphoma, how it announces itself, and what the realistic treatment outcomes look like requires sorting through a complicated body of evidence.

Who Gets HSTCL and Why

HSTCL overwhelmingly favors young men, though the exact male-to-female ratio varies somewhat by subtype.¹ It can appear in people with no identifiable risk factors at all, which is part of what makes it so unsettling. But certain groups face a measurably higher risk.

The most well-documented risk factor is prolonged immunosuppression. People who have received solid organ transplants and remain on long-term anti-rejection medications are vulnerable. A review of cases after organ transplantation found a median survival of just four months among affected recipients, with no other patients in that review surviving beyond 12 months.² The disease has been reported following various types of solid organ transplants, suggesting the underlying immunosuppression rather than the specific organ is the key driver.³

The connection to inflammatory bowel disease (IBD) treatment has drawn particular attention. HSTCL has been linked to thiopurine drugs (azathioprine and 6-mercaptopurine), which are commonly used to manage Crohn’s disease and ulcerative colitis.⁴ Biologic agents like infliximab and adalimumab, especially when used in combination with thiopurines, have also been implicated. As the number of reported cases has grown, the association between these medications and HSTCL development has become difficult to dismiss.⁵ This does not mean everyone on these medications should panic. The absolute risk remains extremely small, but young men on combination immunosuppressive therapy for IBD represent a disproportionate share of reported cases, and that pattern has shaped clinical decision-making around these drugs.

An important wrinkle is that HSTCL can also appear in Crohn’s patients who were never exposed to thiopurines at all, suggesting the chronic immune dysregulation from IBD itself may play a role independent of the medications used to treat it.⁴ This complicates the picture considerably because it means simply avoiding a particular drug does not eliminate the risk entirely.

How HSTCL Presents

The symptoms of HSTCL are maddeningly nonspecific, which is a big reason it often takes a long time to diagnose. Patients typically show up with what clinicians call constitutional symptoms: prolonged unexplained fevers, drenching night sweats, crushing fatigue, and unintentional weight loss. These are the same complaints that could point toward dozens of infections, autoimmune conditions, or other cancers.⁶

What does narrow the differential is the combination of these general symptoms with an enlarged liver and spleen, often dramatically so, alongside low blood counts across all cell lines (red cells, white cells, and platelets). This trio of hepatosplenomegaly plus low blood counts plus constitutional symptoms, especially in a young man without swollen lymph nodes, is a clinical red flag for HSTCL.⁷ The absence of lymph node involvement is actually one of the disease’s distinguishing features and part of what makes it so sneaky: swollen lymph nodes are what often prompt suspicion of lymphoma in the first place, and without that typical signpost, doctors can spend weeks chasing other explanations.

Blood work will typically show low counts, but the abnormalities can initially be mild, which adds to diagnostic delay. Imaging reveals an oversized spleen and liver, but that finding on its own is not specific to any one disease. Ultimately, the diagnosis requires a tissue biopsy, usually of the bone marrow or liver, that identifies the characteristic pattern of malignant T cells infiltrating the sinusoids of these organs.

Hemophagocytic Syndrome as a Complication

One of the more dangerous complications that can accompany HSTCL is hemophagocytic lymphohistiocytosis, sometimes called hemophagocytic syndrome. In this condition, the immune system essentially becomes overactivated, with certain white blood cells attacking and devouring the body’s own blood cells. It causes severe fevers, plummeting blood counts, liver dysfunction, and can be rapidly fatal if not recognized.⁸

The overlap in symptoms between hemophagocytic syndrome and HSTCL itself, both cause fevers, enlarged spleens, and low blood counts, makes this an especially treacherous combination. When a patient with HSTCL rapidly deteriorates, the emergence of hemophagocytic syndrome is one of the first things clinicians need to consider. Treating the underlying lymphoma is ultimately necessary to resolve the syndrome, but supportive care and sometimes specific immunosuppressive therapy are needed to stabilize the patient in the short term.

What Happens at the Cellular and Genetic Level

HSTCL arises from a specific type of immune cell: gamma-delta T cells, which normally patrol the liver and spleen as part of the body’s innate immune surveillance. These cells sit in the sinusoids, the tiny blood channels running through these organs, and it is within those sinusoids that the malignant cells proliferate.⁹ A minority of HSTCL cases arise from alpha-beta T cells rather than gamma-delta T cells, but the clinical behavior and prognosis are similar regardless of which T-cell receptor type the malignant cells carry.

At the chromosomal level, two genetic abnormalities show up with striking consistency. Isochromosome 7q, an abnormal rearrangement of chromosome 7, and trisomy 8, an extra copy of chromosome 8, appear as the primary recurrent chromosomal changes in HSTCL.¹⁰ Multiple studies across both adult and pediatric patients have confirmed these are not random occurrences but characteristic features of the disease.¹¹ One genomic study detected trisomy 8 in about 89 percent of cases examined.¹²

More recent deep-sequencing work has revealed that mutations in genes controlling chromatin modification, the machinery cells use to regulate which genes are turned on and off, are the single most common category of genetic alteration in HSTCL, present in about 62 percent of cases. The gene SETD2 stands out as the most frequently mutated chromatin modifier, with most of its mutations being the type that knocks the gene’s function out entirely. Other commonly mutated genes in this category include INO80, TET3, and SMARCA2. Beyond chromatin-modifying genes, mutations in signaling molecules like STAT5B, STAT3, and PIK3CD also appear frequently.¹³ These signaling mutations matter for a practical reason we will return to shortly: they may represent druggable targets.

Treatment Options

Treating HSTCL has been one of the more frustrating challenges in oncology. Standard lymphoma chemotherapy using anthracycline-based regimens (the workhorse CHOP combination used for many lymphomas) performs poorly against this disease. Platinum-based and cytarabine-containing regimens appear to produce better responses. One retrospective analysis found that all patients treated with an ICE/dexamethasone regimen responded, compared to about half of those treated with anthracycline-based therapy. Complete response rates followed the same pattern: about 83 percent in the ICE/dexamethasone group versus roughly 39 percent with anthracycline-based chemotherapy.¹⁴ Because of findings like these, current thinking generally favors platinum- and cytarabine-containing induction regimens over traditional CHOP.¹⁵

Even when initial chemotherapy achieves a response, HSTCL tends to relapse quickly without further treatment. That is why stem cell transplant has become a critical part of the treatment strategy for patients healthy enough to undergo it. Allogeneic transplant, using donor cells, appears to offer a meaningful survival advantage over autologous transplant, where a patient’s own stem cells are used. A European registry study reported a three-year progression-free survival rate of 48 percent after allogeneic transplant, while patients who underwent autologous transplant relapsed at a higher rate and those who relapsed all died of their disease.¹⁶ The advantage of donor transplant likely comes from a graft-versus-lymphoma effect, where the donor immune system actively fights residual tumor cells in a way the patient’s own immune system cannot.

A U.S. multicenter study confirmed this pattern. Among patients who received allogeneic transplant, the three-year relapse rate was about 35 percent and the transplant-related mortality rate was 16 percent. For autologous transplant recipients, the three-year relapse rate was higher at about 43 percent.¹⁷ Among the entire transplanted cohort, the median overall survival reached roughly 78 months, substantially longer than the approximately one-year median seen in the broader population of HSTCL patients.

Prognosis and Long-Term Survival

Honest conversations about HSTCL prognosis are difficult because the numbers are grim. A population-based analysis using national cancer registry data found one-year overall survival of about 57 percent, dropping to around 38 percent at three years and roughly 32 percent at five years.¹⁸ That same analysis found the survival curve for HSTCL was comparable to another aggressive T-cell lymphoma subtype (PTCL-NOS) but significantly worse than more favorable subtypes.

Single-center data tell a similarly sobering story. A Mayo Clinic series of 22 patients reported a median overall survival of about 12 months and median progression-free survival of about 10 months. Yet that study also identified four patients (about 18 percent of their cohort) who achieved long-term survival ranging from roughly 4.5 years to over 11 years.¹⁹ This is the cautiously hopeful detail buried in the discouraging statistics: a meaningful minority of patients, especially those who respond well to initial chemotherapy and proceed to transplant, do achieve durable remissions.

Pediatric and young adult patients who undergo allogeneic transplant may fare particularly well if their disease responds to chemotherapy. Case reports of adolescents achieving complete remission lasting two to eight years or more after allogeneic transplant exist in the literature, though the numbers are too small to draw confident generalizations.²⁰

Why Diagnosis Takes So Long

One of the most consequential realities of HSTCL is how often it is initially missed. A young person showing up with fevers, fatigue, and a mildly enlarged spleen is far more likely to be evaluated for infectious mononucleosis, malaria, hepatitis, autoimmune disease, or a dozen other conditions before lymphoma enters the conversation. The lack of swollen lymph nodes, which would ordinarily trigger an oncology referral, means the disease can smolder for weeks or months before the correct diagnosis is made.⁶

The rarity of the disease compounds the problem. Most physicians, even experienced hematologists, may see zero or one case in a career. The symptoms mimic infectious causes so convincingly that patients can undergo multiple rounds of empirical antibiotic therapy before anyone considers a tissue biopsy.⁷ When a biopsy is eventually performed, pathologists need to look specifically for the sinusoidal infiltration pattern and the characteristic immunophenotype to make the diagnosis. Standard bone marrow biopsies can miss it if the pathologist is not specifically looking for this entity. The practical takeaway for patients and referring doctors is that unexplained hepatosplenomegaly with falling blood counts in a young person, especially a young man, warrants early bone marrow and possibly liver biopsy rather than prolonged observation.

Emerging Research Into Targeted Therapies

The discovery that STAT5B mutations are common in HSTCL has opened a potential therapeutic avenue. STAT5B is part of the JAK-STAT signaling pathway, and drugs that inhibit JAK enzymes upstream of STAT5B are already approved for other conditions. Recent preclinical work established laboratory models of HSTCL driven by an activating STAT5B mutation and then tested the JAK inhibitor upadacitinib against those models. The results showed strong sensitivity: the drug markedly inhibited abnormal cell growth and triggered cancer cell death both in the lab and in animal models.²¹ These are preclinical results, not human trial data, and the distance between a promising laboratory finding and an approved therapy is long and littered with failures. But for a disease where the standard chemotherapy options are so limited, even early-stage data pointing toward a rational targeted approach generates real interest in the field.

The broader genetic landscape uncovered in HSTCL, with frequent mutations in chromatin-modifying genes and signaling molecules, suggests that this is not a disease where a single magic bullet will work for everyone.¹³ Future treatment strategies may need to be tailored to the specific mutations driving an individual patient’s lymphoma, much as targeted therapy has evolved in other rare cancers. Drugs targeting epigenetic regulators, for instance, are another class under investigation given how frequently chromatin-modifying genes are disrupted. The fundamental challenge remains the disease’s rarity: running large clinical trials for a cancer that strikes a few hundred people per year worldwide requires international collaboration and creative trial designs, both of which are slowly taking shape.

The IBD Medication Dilemma

For patients with Crohn’s disease or ulcerative colitis, the reported association between HSTCL and immunosuppressive therapy creates an uncomfortable risk-benefit calculation. Thiopurines like azathioprine remain among the most effective medications for maintaining remission in IBD, and biologic agents like infliximab have transformed the management of severe disease. The connection to HSTCL is real, but the absolute number of cases is tiny relative to the millions of people worldwide taking these drugs.⁵

In practice, the association has influenced prescribing patterns. Many gastroenterologists have become more cautious about long-term combination therapy (a thiopurine plus a biologic) in young men, the demographic most affected by HSTCL. Some favor using biologics as monotherapy when possible, or opting for newer biologics with different mechanisms of action that have not been linked to HSTCL. The appearance of HSTCL in IBD patients without thiopurine exposure, however, complicates any simple avoidance strategy.⁴ It suggests that uncontrolled inflammation itself carries risk, and that the decision should not be framed as simply “medication risk versus no risk” but rather as “medication risk versus disease-related risk.” That kind of nuanced conversation between patient and doctor, ideally incorporating the patient’s specific demographics, disease severity, and available alternatives, is where the real decision-making happens.